


Biotechnology in the United States*

In 2003, 2,196 firms were undertaking biotechnology R&D, represented 6 per cent of all R&D-active firms. These firms spent PPP\$ 14,232 million on biotechnology R&D, or 7 per cent of the total business enterprise R&D expenditures.

The majority of firms undertaking biotechnology R&D in 2003 were in the non-manufacturing sector and these constituted: 73 per cent or 1,609 firms. These firms were responsible for spending 62 per cent of all biotechnology R&D expenditures; the remainder was spent by the manufacturing sector.

The Scientific and R&D services sector in the non-manufacturing branch (North American Industry Classification System (NAICS) code 5417) had the highest share of biotechnology R&D expenditures: 36


US-based Firms undertaking Biotechnology R&D in the Business Enterprises Sector (NAICS), 2003



* Based on OECD (2006).

per cent of all biotechnology R&D expenditures. The Pharmaceuticals and Medicine sector in the manufacturing branch (NAICS code 3254) had the second largest share, with 32 per cent of total biotechnology R&D expenditures.

Ninety percent of the firms undertaking biotechnology R&D were Small and Medium-Sized Enterprises (SMEs) with fewer than 250 employees. However, these SMEs accounted for only PPP\$ 3,614 million of biotechnology R&D, or 25 per cent of the total.



US Biotechnology R&D by application field, Million PPP\$, 2001

